604 related articles for article (PubMed ID: 26665262)
21. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.
Wynn RL
Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815
[No Abstract] [Full Text] [Related]
22. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
23. Immediate Implant Placement in a Patient With Osteoporosis Undergoing Bisphosphonate Therapy: 1-Year Preliminary Prospective Study.
Siebert T; Jurkovic R; Statelova D; Strecha J
J Oral Implantol; 2015 Jul; 41 Spec No():360-5. PubMed ID: 24041299
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
Hamdy RC
Drug Des Devel Ther; 2010 Nov; 4():321-35. PubMed ID: 21151620
[TBL] [Abstract][Full Text] [Related]
25. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.
Couture G; Delzor F; Bagheri H; Micallef J; Ruyssen-Witrand A; Laroche M
Joint Bone Spine; 2017 Mar; 84(2):213-215. PubMed ID: 27939801
[TBL] [Abstract][Full Text] [Related]
26. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw.
Shin JW; Kim JE; Huh KH; Yi WJ; Heo MS; Lee SS; Choi SC
Sci Rep; 2024 Apr; 14(1):8744. PubMed ID: 38627515
[TBL] [Abstract][Full Text] [Related]
27. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
28. Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant.
Miniello TG; Araújo JP; Lopes RN; Alves FA
Braz Dent J; 2015; 26(1):86-8. PubMed ID: 25672391
[TBL] [Abstract][Full Text] [Related]
29. Intravenous zoledronic acid for the treatment of osteoporosis.
Lewiecki EM
Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Barba-Recreo P; Del Castillo Pardo de Vera JL; García-Arranz M; Yébenes L; Burgueño M
J Craniomaxillofac Surg; 2014 Sep; 42(6):744-50. PubMed ID: 24342733
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Nomura T; Shibahara T; Uchiyama T; Yamamoto N; Shibui T; Yakushiji T; Watanabe A; Muramatsu K; Ogane S; Murayama M; Sekine R; Nakata E; Fujimoto Y
Bull Tokyo Dent Coll; 2013; 54(2):117-25. PubMed ID: 23903583
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Osteonecrosis of the Jaw.
Yamachika E; Matsubara M; Ikeda A; Matsumura T; Moritani N; Iida S
J Craniofac Surg; 2015 Oct; 26(7):e575-7. PubMed ID: 26468825
[TBL] [Abstract][Full Text] [Related]
33. Experimental model of osteonecrosis of the jaw in rats treated with zoledronic acid.
Kolpakova ME; Zubarevа AA; Artamonova TD; Lisovskaya EK; Chefu SG; Yagmurov OD; Yaremenko AI; Vlasov TD
Br J Oral Maxillofac Surg; 2017 Feb; 55(2):156-159. PubMed ID: 27780611
[TBL] [Abstract][Full Text] [Related]
34. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
[No Abstract] [Full Text] [Related]
36. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
37. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
[TBL] [Abstract][Full Text] [Related]
38. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis.
Mattheos N; Caldwell P; Petcu EB; Ivanovski S; Reher P
J Can Dent Assoc; 2013; 79():d2. PubMed ID: 23763726
[TBL] [Abstract][Full Text] [Related]
39. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
[TBL] [Abstract][Full Text] [Related]
40. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
